Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor

Jessica Huyet, Grégory M. Pinon, Michel R. Fay, Jérôme Fagart, and Marie-Edith Rafestin-Oblin

Institut National de la Santé et de la Recherche Médicale, U773, Centre de Recherche Biomédicale Bichat Beaupré CRB3, BP 416, Paris, France; and Université Paris 7 Denis Diderot, site Bichat, BP 416, Paris, France

Received March 27, 2007; accepted June 12, 2007

ABSTRACT

Spirolactones are potent antagonists of the mineralocorticoid receptor (MR), a ligand-induced transcription factor belonging to the nuclear receptor superfamily. Spirolactones are synthetic molecules characterized by the presence of a C17 γ-lactone, which is responsible for their antagonist character. They harbor various substituents at several positions of the steroid skeleton that modulate their potency in ways that remain to be determined. This is particularly obvious for C7 substituents. The instability of antagonist-MR complexes makes them difficult to crystallize. We took advantage of the S810L activating mutation in MR (MRs810L), which increases the stability of ligand-MR complexes to crystallize the ligand-binding domain (LBD) of MRs810L associated with 7α-acetyltio-17β-hydroxy-3-oxopregn-4-en-21-carboxylic acid γ-lactone (SC9420), a spirolactone with a C7 thioacetyl group. The crystal structure makes it possible to identify the contacts between SC9420 and MR and to elucidate the role of Met852 in the mode of accommodation of the C7 substituent of SC9420. The transactivation activities of MRs810L-C7TA, MRs810L-M817A, and MRs810L-N770A reveal that the contacts between SC9420 and the Gln776 and Arg817 residues are crucial to maintaining MRs810L in its active state, whereas the contact between SC9420 and the Asn770 residue contributes only to the high affinity of SC9420 for MR. Moreover, docking experiments with other C7-substituted spirolactones revealed that the MRs810L-activating potency of spirolactones is linked to the ability of their C7 substituent to be accommodated in LBD. It is remarkable that the MRs810L-activating and MRWT-inactivating potencies of the C7-substituted spirolactones follow the same order, suggesting that the C7 substituent is accommodated in the same way in MRs810L and MRWT. Thus, the MRs810L structure may provide a powerful tool for designing new, more effective, MR antagonists.

Aldosterone plays a major role in regulating sodium and potassium homeostasis in tight epithelia, including the distal tubule of the kidney, the distal colon, and the salivary and sweat glands (Hirsonberger and Rossier, 1992; Bonvalet, 1998). It may also exert pathophysiological effects in nonepithelial target tissues, such as the adipose tissue (Penfornis et al., 2000) and the cardiovascular system, where it contributes to controlling blood pressure and is implicated in some disorders, such as hypertension (Rossi et al., 2005).

Aldosterone exerts its effects by binding to the mineralocorticoid receptor (MR), a ligand-activated transcription factor that is a member of the nuclear receptor superfamily (Mangelsdorf et al., 1995; Gronemeyer et al., 2004). Aldosterone-dependent activation of gene transcription is thought to be a multistep process. In its ligand-free state, MR is predominantly located in the cytoplasm, where it is associated with a protein complex, including the 90-kDa heat shock protein. When aldosterone binds to MR this induces a receptor conformation change that in turn leads to the dissociation of the associated proteins, the transfer of the complex into the nucleus, and the subsequent recruitment of transcriptional coactivators (Trapp et al., 1995; Couette et al., 1996; Fejes-Tóth et al., 1998; Hellal-Levy et al., 2000; Hultman et al., 2005).

Spirolactones are MR antagonists that have been widely used for the past 30 years in the treatment of sodium-retaining states and as antihypertensive agents. They improve survival in heart failure, and they have beneficial effects in preventing the development of cardiac fibrosis and renal

ABBREVIATIONS: SC9420, 7α-acetyltio-17β-hydroxy-3-oxopregn-4-en-21-carboxylic acid γ-lactone (spironolactone); RU26752, 7α-propyl-17β-hydroxy-3-oxopregn-4-en-21-carboxylic acid γ-lactone; LBD, ligand-binding domain; 18OVP, 18-oxo-18-vinylprogesterone; GST, glutathione transferase; PDB, Protein Data Bank; HEK, human embryonic kidney; MMTV, mouse mammary tumor virus; MR, mineralocorticoid receptor.
damage in patients with essential hypertension (Pitt et al., 1999, 2003; Garthwaite and McMahon, 2004). Spirolactones are synthetic molecules with a C17 \( \gamma \)-lactone that is responsible for their antagonist activity and various other substituents on the steroid skeleton that modulate their potency (Corvol et al., 1977; Nickisch et al., 1985; de Gasparo et al., 1987; Elger et al., 2003; Fagart et al., 2005a); this is particularly evident in the case of the C7 substituents. SC9420, a member of the spirolactone family, characterized by the presence of a C7 thioacetyl group, and RU26752, which has a C7 propyl group, more potently inactivate MR<sub>WT</sub> than mrenoren, which harbors a C7 carboxymethyl ester group, or canrenone, which has no C7 substituent (Fagart et al., 2005a). In this study, we set out to elucidate how the C7 substituent regulates the antagonist potency of spirolactones.

The crystal structure of the ligand-binding domain (LBD) of MR when it is associated with an agonist is now available (Bledsoe et al., 2005; Fagart et al., 2005b; Li et al., 2005). It is likely that the high stability of the agonist-MR complexes has facilitated their purification and crystallization. In contrast, the low stability of the antagonist-MR complexes (Fagart et al., 1998) has made it impossible to determine the structure of the MR-LBD associated with an antagonist ligand. It is noteworthy that the S810L mutation, which is responsible for a severe familial form of hypertension, increases the stability of ligand-MR complexes, and switches the crystal structure of MRS810L-LBD associated with SC9420 into an antagonist to an agonist (Geller et al., 2000; Gouilleux et al., 1991). The expression vector pMRLBDL810 contains the coding sequence for the fusion protein between GST and MR-LBD that harbors the S810L and C910A mutations (Fagart et al., 2005b).

**Protein Expression and Purification.** Fermentation using the BL21 CodonPlus (DE3) RIL strain from Stratagene (Amsterdam, The Netherlands) transformed with the pMRLBDL810 vector was carried out in the presence of 100 \( \mu \)M SC9420. Expression was induced by incubating with 200 \( \mu \)M isopropyl-\( \beta \)-thiogalactoside for 16 h at 15°C. After centrifuging, the bacteria were disrupted by sonication in TENG buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, and 0.1% n-octyl-\( \beta \)-glucoside) supplemented with 100 \( \mu \)M SC9420. The lysate was clarified and loaded onto a GSTrap column (GE Healthcare, Les Ulis, France). The fusion protein was eluted with 15 mM reduced glutathione in the TENG buffer. After diluting the eluate to a protein concentration of 1 mg/ml, the fusion protein was cleaved by exposing to thrombin protease (20 units/mg of fusion protein) overnight at 4°C. The protein mixture was diluted a further 5-fold in a HENG buffer (10 mM HEPES, pH 6.8, 10% glycerol, and 0.1% n-octyl-\( \beta \)-glucoside) supplemented with 100 \( \mu \)M SC9420, loaded onto a sulfoxide column (SP XL from GE Healthcare), and eluted with a gradient of 0 to 500 mM NaCl in the HENG buffer. The fractions containing the LBD were pooled and concentrated to a protein concentration of 7 mg/ml.

**Crystallization and Data Collection.** Crystals were grown over a few days at room temperature in hanging drops containing 1 \( \mu \)l of protein solution and 1 \( \mu \)l of well buffer (100 mM HEPES, pH 6.8, 130 mM NaCl, and 25% PEG 4000). Before data collection, the crystals were flash-frozen in liquid nitrogen without adding any cryoprotecting agent. Diffraction data were collected to a resolution of 2.29 Å, at a temperature of ~80.1°C and at a wavelength of 0.979707 Å on the FIP-BM30A beamline at the European Synchrotron Radiation Facility (ESRF, Grenoble, France) using a MarCCD detector. The data set was integrated and scaled using XDS (Kabsch, 1993).

**Structure Determination and Refinement.** The crystal structure was determined by molecular replacement, using Phaser (Storoni et al., 2004) with the coordinates of the MR<sub>S810L</sub>-LBD associated with deoxycorticosterone (PDB ID 1Y9R; Fagart et al., 2005b) as the search model. The crystal was crystallized in the P<sub>3</sub> space group. From molecular replacement, two rotation solutions clearly appeared, and three translation solutions were obtained for each of these rotation solutions, indicating the presence of six molecules in the asymmetric unit. Several rounds of manual rebuilding using the SSM software weighted 2 \( F_{o} \)-\( F_{c} \) electron density maps, followed by simulated annealing and individual isotropic B factor refinements were performed using CNS (Brüger et al., 1998). Solvent molecules were located in a \( F_{o} \)-\( F_{c} \) map contoured at 2.5\( \sigma \). The final R and R free values were 24 and 26.3%, respectively. The final model was validated with PROCHECK (Laskowski et al., 1993); 99.7% of the residues lie within the allowed regions of the Ramachandran Plot.

**Determination of the Cavity Volumes.** The volume of the ligand-binding cavity of MR<sub>S810L</sub>-LBD associated with SC9420, and that of MR<sub>S810L</sub>-LBD associated with progesterone, were calculated using the probe-occupied algorithm of the VOIDOO package (Kleywegt and Jones, 1994). This algorithm uses a probe sphere with a radius of 1.4 Å. The contacts between the probe sphere and the van der Waals protein surface delineate the probe-occupied cavity. The volume of the ligand-binding cavity of MR<sub>S810L</sub>-LBD associated with SC9420, and that of MR<sub>S810L</sub>-LBD associated with progesterone, were calculated for each monomer of the asymmetric unit. The values reported under Results are the means of the monomer volumes.

**Docking Experiments.** RU26752 and mrenoren were constructed and minimized using the Insight II package (Accelrys, Camarillo, CA) and the GOLD program (CCP4 and the CCP4 suite, 1994) using the SC9420 structure as the template.

---

**Materials and Methods**

**Chemicals.** Aldosterone (4-pregnen-11β,21-diol-18-al-3,20-dione), progesterone (4-pregnen-3,20-dione), and SC9420 were purchased from Sigma-Aldrich (St Louis, MO). RU26752 was kindly provided by Sanofi-Aventis (Paris, France). Canrenone was provided by Pfizer Inc. (New York, NY). Mrenoren was a gift from G. Auzou (Institut National de la Santé et de la Recherche Médicale U540, Montpellier, France). 18-oxo-18-Vinylprogesterone (18-vinyl-4-pregnen-3,18,20-trione; 18OVP) was a gift from A. Marquet (Paris, France). All other products used in the biochemical studies were purchased from Sigma-Aldrich (St Louis, MO).

**Expression Vectors.** The expression vector pchMR<sub>WT</sub> contains the entire coding sequence of wild-type human MR (Fagart et al., 1998). The expression vectors pchMR<sub>N770A</sub>, pchMR<sub>S810L</sub>, pchMR<sub>S810LQ776A</sub>, and pchMR<sub>S810LQ776A/S817A</sub> contain the coding sequences of mutant MR<sub>N770A</sub>, MR<sub>S810L</sub>, MR<sub>S810LQ776A</sub>, and MR<sub>S810LQ776A/S817A</sub>, respectively (Fagart et al., 1998, 2005b; Rafestin-Obin et al., 2003). The expression vector pchMR<sub>S810LQ776A/S817A</sub> was created by cutting out the Bpu1102I-APHI fragment from pchMR<sub>S810L</sub> and inserting it into pchMR<sub>N770A</sub>. The plasmid pFC31Luc contains the MMTV promoter that drives the luciferase gene (Gouilleux et al., 1991). The expression vector pMRLBDL810 contains the coding sequence for the fusion protein between GST and MR-LBD that harbors the S810L and C910A mutations (Fagart et al., 2005b).
bridge, UK). Both spirolactones were manually docked within the crystal structure of the MR
S810L-LBD associated with SC9420 using the O package (Jones et al., 1991).

Cells Culture and Transfection Procedures. HEK 293T cells were cultured in high-glucose-containing Dulbecco’s minimal essential medium (Invitrogen, Cergy Pontoise, France), 25 mM HEPES, 2% nonessential amino acids, 2 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin, supplemented with 10% heat-inactivated fetal calf serum at 37°C in a humidified atmosphere and with 5% CO2. Four hours before transfection, the cells were cultured in the same medium supplemented with 10% charcoal-treated fetal calf serum. Transfections were carried out using the calcium phosphate precipitation method. Cells were transfected with 2 µg of one of the receptor expression vectors (pchMRWT, pchMRN770A, pchMRSS10L, pchMRSS10LN770A, pchMRSS10LQ776A, or pchMRSS10LR817A), 7 µg of pFC31Luc and 1 µg of pβgal in 1× HEPES-buffered saline supplemented with 160 mM CaCl2. Twelve hours after transfection, the cells were rinsed with phosphate-buffered saline, trypsinized, and replated in 12-well plates. The steroids to be tested were added to the cells 24 h after seeding. After incubating for 24 h, cell extracts were assayed for luciferase and β-galactosidase activities (Herbomel et al., 1984; de Wet et al., 1987). To standardize the transfection efficiency, the relative light units obtained in the luciferase assay were divided by the optical density obtained in the β-galactosidase assay. Each point is the mean ± S.E.M. of three separate experiments.

Results

Effects of the C7 Substituent of Spirolactones on the Agonist Activity of MR
S810L. It has been reported that SC9420, a spirolactone with a C7 thioacetyl group, activates the MR carrying the S810L mutation (MR
S810L) (Geller et al., 2000). We wondered whether spirolactones lacking C7 substituent (canrenone) or harboring a C7 substituent distinct from that of SC9420 (RU26752 and mexrenone; see formulae in Fig. 1) are also able to activate MR
S810L. We investigated the ability of these spirolactones to activate MR
S810L transiently expressed in HEK293T cells. Transfection assays performed with pchMRSS10L revealed that RU26752, which is characterized by having a C7 propyl group, activates MR
S810L as potently as SC9420 and has an ED50 value of ~10−11 M, close to that of aldosterone (ED50 ~ 5 × 10−11 M) (Fig. 2). Mexrenone, with a C7 carboxymethyl ester group, is less potent than SC9420 (ED50 ~ 10−10 M) (Fig. 2). Canrenone, which has no C7 substituent, displays lower agonist activity corresponding to ~60% of the maximum aldosterone-induced MR
S810L activity (Fig. 2) and has no antagonist activity (data not shown). Thus, all the spirolactones tested activate MR
S810L and their potencies depend on the C7 substituents. It is interesting that the MR
S810L-activating and MR
WT-inactivating (Fagart et al., 2005a) potencies of the C7-substituted spirolactones follow the same order, suggesting that the C7 substituent is accommodated in the same way in MR
S810L and MR
WT.

Crystal Structure of the Ligand-Binding Domain of MR
S810L Associated with SC9420. To identify the accommodation mode of SC9420 within the ligand-binding cavity of MR, we solved the crystal structure of the LBD of MR
S810L associated with SC9420. The MR
S810L-LBD was expressed as a fusion protein with glutathione transferase (GST) in the presence of a high concentration of SC9420 and then purified according to the protocol described previously (Fagart et al., 2005b). In brief, the fusion protein was purified by affinity chromatography and cleaved by the action of the thrombin protease. The LBD was separated from GST by cation exchange chromatography and then crystallized by the vapor diffusion method. The structure was solved by molecular replacement, using the crystal structure of MR
S810L-LBD associated with deoxycorticosterone as a template (PDB ID 1Y9R; Fagart et al., 2005b) and was then refined to 2.3 Å resolution (see Table 1). The complex crystallized in the P321 space group with six molecules in the asymmetric unit (see Table 1). MR
S810L-LBD associated with SC9420 is composed of 11 α-helices (H1, H3–H12) and two short β-sheets, organized into three layers. The quality of the density map made it possible to pinpoint the position of SC9420 accurately in the ligand-binding cavity (Fig. 3A). This cavity is lined by 22 residues, five of which are polar, and three anchor the ligand (Fig. 3B). The C3 ketone function of SC9420 is hydrogen bound to the Gln776 and Arg817 residues and to a water molecule (Fig. 3B). The ketone function of the C17 γ-lactone of SC9420 establishes a hydrogen bond with the Asn770 residue (Fig. 3B). Seventeen residues contribute to the hydrophobic nature of the binding cavity and stabilize the position of SC9420 through numerous van der Waals contacts (Fig. 3B). The Leu810 residue forms short hydrophobic contacts with the C19 methyl group of SC9420 and with the Gln776 residue (Fig. 3. A and B). The C7 thioacetyl group of SC9420 is clearly defined in the electron density map (Fig. 3A). It is accommodated within a small hydrophobic groove delimited by Ser811 (H5), Leu814 (H5), Leu827 (β-turn), Phe829 (β-turn), Met845 (H7), Cys849 (H7), Met852 (H7), and Leu838 (H11) (Fig. 3B), where it establishes numerous van der Waals contacts.

We next compared the crystal structure of MR
S810L associated with SC9420, with that of MR
S810L associated with progesterone, a ligand with no C7 substituent (PDB ID 1Y9A;
Fagart et al., 2005b). The orientations of the Ser811, Met845, and Met852 residue side chains of the ligand-binding cavity are modified (compare Fig. 4A and B). The slight changes in the orientation of the Ser811 and the Met845 residue side chains modify neither the van der Waals volume occupied by these residues nor the volume of the ligand-binding cavity. In contrast, changing the orientation of the Met852 residue has a drastic impact. Its side chain adopts a folded-back conformation in the presence of the C7-substituted SC9420 (Fig. 4A) that is different from the extended conformation observed with progesterone, a steroid with no C7 substituent (Fig. 4B). Accordingly, the volume of the ligand-binding cavity of MRSS10L associated with SC9420 is larger than that of MRSS10L associated with progesterone (499 Å³ versus 406 Å³) (Fig. 4, A and B). Thus, the presence of the C7 thioacetyl group of SC9420 modifies the conformation of the Met852 side chain, creating a small groove within which the C7 substituent is accommodated and establishes numerous contacts.

Finally, we compared the crystal structure of MRSS10L associated with SC9420, and that of MRWT, associated with deoxycorticosterone, a molecule that activates both MRWT and MRSS10L (PDB ID 2ABI). Superimposing the two structures reveals that the overall organization of the two structures is very similar, the positioning of all 11 helices being the same (Fig. 5A). Superimposing the ligand-binding cavity of MRSS10L associated with SC9420, over that of MRWT, associated with deoxycorticosterone, shows that the Leu810 residue establishes short hydrophobic contacts with the C19 methyl group of SC9420 (Fig. 5B). The superimposition of the two structures also reveals that the network of contacts, created by the Leu810 residue, does not exist in the MRWT (Fig. 5B). Thus, the S810L mutation does not modify the overall organization of the receptor but does allow additional contacts to occur that stabilize the receptor in its active state.

C7-Substituted Spirolactones Docking within the MRSS10L-LBD. To find out how the C7 side chain of RU26752 and mexrenone can be accommodated within the ligand-binding cavity, we determined the lowest energy conformation of the C7 substituents of spirolactones by performing rotation searches and docked these molecules within the structure of MRSS10L-LBD associated with SC9420. The orientation of the thioacetyl group of SC9420 determined by the lowest energy conformation search is the same as observed in the crystal structure, suggesting that no modification of the C7 substituent orientation occurs when SC9420

### Table 1

<table>
<thead>
<tr>
<th>Data collection and refinement statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MRSS10L–SC9420</strong></td>
</tr>
<tr>
<td>Space group</td>
</tr>
<tr>
<td>Cell dimensions:</td>
</tr>
<tr>
<td>a, b, c (Å)</td>
</tr>
<tr>
<td>α, β, γ (°)</td>
</tr>
<tr>
<td>Resolution (Å)</td>
</tr>
<tr>
<td>R&lt;sub&gt;merge&lt;/sub&gt;</td>
</tr>
<tr>
<td>I / σ I</td>
</tr>
<tr>
<td>Completeness (%)</td>
</tr>
<tr>
<td>Redundancy</td>
</tr>
<tr>
<td>Refinement:</td>
</tr>
<tr>
<td>Resolution (Å)</td>
</tr>
<tr>
<td>No. of reflections</td>
</tr>
<tr>
<td>R&lt;sub&gt;work&lt;/sub&gt; / R&lt;sub&gt;free&lt;/sub&gt;</td>
</tr>
<tr>
<td>No. of atoms</td>
</tr>
<tr>
<td>Protein</td>
</tr>
<tr>
<td>Ligand/ion</td>
</tr>
<tr>
<td>Water</td>
</tr>
<tr>
<td>B-factors:</td>
</tr>
<tr>
<td>Protein</td>
</tr>
<tr>
<td>Ligand/ion</td>
</tr>
<tr>
<td>Water</td>
</tr>
<tr>
<td>Root-mean-square deviations</td>
</tr>
<tr>
<td>Bond lengths (Å)</td>
</tr>
<tr>
<td>Bond angles (°)</td>
</tr>
</tbody>
</table>

* One crystal was used to collect the data.

*Highest resolution shell is shown in parenthesis.

---

Fig. 2. Effect of spirolactones on the MRSS10L transactivation activity. HEK 293T cells transiently expressing MRSS10L were incubated for 24 h with increasing concentrations (10⁻¹¹–10⁻⁶ M) of aldosterone (ALDO), SC9420, RU26752, mexrenone (MEX), or canrenone (CAN). The transactivation activities of MRSS10L were determined from the luciferase activity normalized in terms of the -galactosidase activity. Results are expressed as a percentage of MRSS10L activity in response to 10⁻⁹ M aldosterone. Values are mean ± S.E.M. of three separate experiments.

Fig. 3. Crystal structure of the MRSS10L-LBD associated with SC9420. A, stereo view of the 2F<sub>e</sub> – F<sub>c</sub> electron density map showing SC9420, and the surrounding residues in the MRSS10L-LBD. The map was calculated at 2.29 Å and contoured at 1σ. This figure was produced using DINO (http://www.dino3d.org). B, diagram showing the interactions between MRSS10L-LBD and SC9420. Hydrogen bonds and van der Waals interactions are depicted as solid red arrows and dashed black lines, respectively. W indicates a water molecule.
binds to MR_{SS10L} (Fig. 6A). The minimized conformations search reveals that the propyl group of RU26752 is oriented in the same way as the thioacetyl group of SC9420, and docking experiments show that it fits well into the groove created by the folded-back conformation of the Met852 residue, where it establishes numerous contacts (Fig. 6B). In contrast, the minimization of mexrenone shows that the orientation of its C7 side chain is different from that of SC9420. The docking experiment of the minimized mexrenone within the crystal structure of MR_{S810L}-LBD associated with SC9420 reveals that its C7 substituent is too close to the Phe829 and the Leu938 residues, leading to unfavorable contacts (Fig. 6C). The rotation of the C7 side chain would be possible, but would necessitate energy-consuming adaptation of the receptor and/or of mexrenone. Thus, the accommodation mode of the C7 substituent of spirolactones is directly linked to their structure.

**Activation Mechanism of the MR_{SS10L} by Spirolactones.** The structure revealed that SC9420 is anchored by several hydrogen bonds, between the C3 ketone function and the Gln776 and the Arg817 residues and between the C17 γ-lactone and the Asn770 residue. Which contacts are involved in stabilizing spirolactone-MR_{SS10L} in its active state? To identify these contacts, we replaced the polar residues Asn770, Gln776, or Arg817 by an alanine within MR_{SS10L} and then tested the ability of spirolactones with various C7 substituent to activate the corresponding double-mutant receptors (MR_{SS10L/Asn770A}, MR_{SS10L/Gln776A}, and MR_{SS10L/Arg817A}). Transfection assays performed with pchMR_{SS10L/Gln776A} and pchMR_{SS10L/Arg817A} showed that all the spirolactones tested were unable to activate MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} (data not shown), which contrasted with their ability to activate MR_{SS10L}. The next question was whether spirolactones act as antagonist ligands when bound to MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A}. To answer this question, HEK 293T cells transiently expressing MR_{SS10L/Gln776A} or MR_{SS10L/Arg817A} were incubated with aldosterone, in the presence of rising concentrations of spirolactones. Aldosterone has been reported to activate MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} with ED_{50} values of $10^{-7}$ and $10^{-6}$ M, respectively (Fagart et al., 2005b). RU26752 and SC9420 inhibit the aldosterone-induced transactivation activities of MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} in a dose-dependent manner with IC_{50} values ranging from 1 to $5 \times 10^{-7}$ M (Fig. 7, A and B). Mexrenone and canrenone also inhibited the aldosterone-induced transactivation activities of MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} but with less potency, their IC_{50} values ranging from 5 to $10 \times 10^{-6}$ M (Fig. 7, A and B). Thus, the Q776A and the R817A mutations within MR_{SS10L} abolish the agonist character that spirolactones display when bound to the MR_{SS10L}. In addition, the potency of spirolactones for inactivating MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} follows the same order as that for activating MR_{SS10L} (RU26752 > SC9420 > mexrenone > canrenone). Overall, these findings indicate that the S810L mutation stabilizes the spirolactone-receptor complexes in their active state, by reinforcing their contacts with the Gln776 and the Arg817 residues without modifying their potencies.

We then investigated the role of the Asn770 residue in MRS810L activation by spirolactones. Progesterone activated MR_{SS10L/Asn770A} with an ED_{50} value of $5 \times 10^{-9}$ M, but aldosterone did not (data not shown). We therefore used progesterone as an agonist ligand in the transfection assays performed with pchMR_{SS10L/Asn770A}. At a concentration of $5 \times 10^{-5}$ M, RU26752 induced 60% of the maximum progesterone-induced MR_{SS10L/Asn770A} activity (Fig. 8A). At the same concentration, SC9420, mexrenone, and canrenone inhibited the aldosterone-induced transactivation activities of MR_{SS10L/Gln776A} and MR_{SS10L/Arg817A} (data not shown), which contrasted with their ability to activate MR_{SS10L}.
renone activate MR_{SS10L,N770A} by 13, 10, and 3%, respectively (Fig. 8A). The question then arose as to whether spirolactones would display antagonist properties when bound to MR_{SS10L,N770A}. Transfection assays performed with pchMR_{SS10L,N770A} revealed that at a concentration of $10^{-5}$ M, SC9420 inhibited progesterone-induced MR_{SS10L,N770A} activity by 75%, whereas RU26752, mexrenone, and canrenone antagonized the effects of progesterone by only 11, 29, and 27%, respectively (Fig. 8B). Spirolactones modified the transactivation properties of MR_{SS10L,N770A} only at a high concentration ($10^{-5}$ M). As the N770A mutation within MR_{SS10L} dramatically reduced the ability of spirolactones both to activate and inactivate the receptor, it seems likely that it must play a key role in the affinity of spirolactones for MR_{SS10L}.

**Role of the Asn770 Residue in MR_{WT}**. It has been reported that the antagonist character of spirolactones when bound to the MR_{WT} is due to their inability to establish contact with the Asn770 residue (Fagart et al., 1998). We observed here that the contact between spirolactones and the Asn770 residue is important for their high affinity for MR_{SS10L}. This led us to wonder whether the Asn770 residue also contributes to the high affinity of spirolactones for MR_{WT}. The Asn770 residue was replaced by an alanine in the context of the wild-type receptor, and the ability of the corresponding mutant MR_{N770A} to be inactivated by spirolactones was tested and compared with that of MR_{WT}. The synthetic compound 18OVP was used in the transfection assays because it is able to activate both MR_{WT} and MR_{N770A} with the same potency (ED$_{50}$ values of $\sim5 \times 10^{-8}$ M) (Souque et al., 1995; Fagart et al., 1998). SC9420, RU26752, mexrenone, and canrenone very potently inhibited the MR_{WT} activity induced by 18OVP (Fig. 9A). Complete inhibition was observed for a concentration of spirolactones of $10^{-6}$ M (Fig. 9A). After the N770A mutation within MR_{WT}, all the spirolactones retained their antagonist character, but they displayed lower potency (Fig. 9B). At $10^{-6}$ M, SC9420, mexrenone, and canrenone inhibited the 18OVP-induced MR_{N770A} activity by 20 to 45%, compared with more than 90% inhibition of the MR_{WT} (Fig. 9B). The antagonist potency of RU26752 was also decreased but to a lesser extent. Indeed, at a concentration of $10^{-7}$ M, RU26752 inhibited the 18OVP-induced activity of MR_{WT} and MR_{N770A} by 90 and 40%, respectively (Fig. 9B). Thus, it can be suggested that the Asn770 residue may play a key role in the affinity of spirolactones for MR_{WT}.

---

**Fig. 6.** Spirolactones within the ligand-binding cavity of MR_{SS10L}. A, superimposition of the minimized SC9420 (blue) over the SC9420 in the crystal structure (gray) within the ligand-binding cavity of MR_{SS10L}. Docking of the lowest energy conformations of RU26752 (B) and mexrenone (C) within the ligand-binding cavity of MR_{SS10L}. Van der Waals volumes of the C7 substituent are depicted in red and those of Phe829 and Leu938 in black. The figure was generated using Open PyMol version 0.93.

**Fig. 7.** Transactivation properties of MR_{SS10L,Q776A} and MR_{SS10L,R817A} in response to spirolactones. HEK 293T cells transiently expressing MR_{SS10L,Q776A} (A) and MR_{SS10L,R817A} (B) were incubated for 24 h with $10^{-7}$ M aldosterone in the absence (100% agonist activity) or presence of increasing ($10^{-5}$ to $10^{-2}$ M) concentrations of SC9420, RU26752, mexrenone (MEX), and canrenone (CAN). Transactivation activities of mutant MRs were determined from the luciferase activity normalized in terms of the $\beta$-galactosidase activity. Values are mean ± S.E.M. of three separate experiments.
Discussion

The present study shows that spirolactones activate the MR harboring the S810L mutation, which is responsible for hypertension, whereas they act as antagonists when bound to the wild-type receptor. It also indicates that the potencies of spirolactones in activating MR_{S810L} and inactivating MR_{WT} follow the same order, allowing us to propose that the contacts involved in MR_{S810L}-activation by spirolactones may be different from those that modulate their potency.

The understanding of the activation mechanism of nuclear receptors has been greatly improved by crystallographic studies of LBDs in their inactive and active states. The LBD of nuclear receptors that surrounds the ligand-binding cavity is rather dynamic and exhibits some of the properties of a molten globule in the absence of ligand (Nagy and Schwabe, 2004). Binding a ligand compacts the LBD by establishing many polar and hydrophobic contacts. Some of these are involved in the stability of the ligand-receptor complex, and others are required to stabilize the complex in its active state, facilitating the recruitment of transcriptional coactivators (Nagy and Schwabe, 2004). Several structures of the LBD of MR in its agonist conformation are now available (Bledsoe et al., 2005; Fagart et al., 2005b; Li et al., 2005). In contrast, no structure of MR in its apo and antagonist conformation is yet available, making it impossible to identify the conformational changes that take place in response to agonist or antagonist binding. Nevertheless, a few years ago, it was shown that the contact between the Asn770 residue of MR_{WT} and the C21 hydroxyl function of aldosterone, or the C11 hydroxyl function of 11β-hydroxyprogesterone, is responsible for the agonist character of these molecules (Fagart et al., 1998; Rafestin-Oblin et al., 2002). In contrast, the MR antagonists, such as progesterone or spirolactones, are unable to contact the Asn770 residue (Fagart et al., 1998). Thus, the mechanism by which antagonist ligands inactivate the MR is based on the instability of the antagonist-MR complexes, rather than on the ability of the antagonist ligand to stabilize the MR in an inactive state, favoring the recruitment of corepressors (Fagart et al., 1998).

In this study, transactivation experiments revealed that spirolactones activate MR, harboring the S810L mutation (MR_{S810L}). These results raised the question of how the S810L mutation modifies spirolactone-receptor contacts, allowing MR_{S810L} to be maintained in its active state. The

Fig. 8. Transactivation properties of MR_{S810L/N770A} in response to spirolactones. A, HEK 293T cells transiently expressing MR_{S810L/N770A} were incubated for 24 h with 10⁻⁷ M progesterone (P) or 10⁻⁷ to 10⁻⁵ M spirolactones to be tested. Results are expressed as the percentage of the MR_{S810L/N770A} activity in response to 10⁻⁷ M progesterone. B, HEK 293T cells transiently expressing MR_{S810L/N770A} were incubated for 24 h with 10⁻⁷ M progesterone in the presence of increasing (10⁻⁷ M–10⁻⁵ M) concentrations of the spirolactones tested. Transactivation activities of MR_{S810L/N770A} were determined from the luciferase activity normalized in terms of the β-galactosidase activity. Values are mean ± S.E.M. of three separate experiments.

Fig. 9. Transactivation properties of MR_{WT} and MR_{N770A} in response to spirolactones. HEK 293T cells transiently expressing MR_{WT} (A) or MR_{N770A} (B) were incubated for 24 h with 10⁻⁷ M 18OVP in the absence (100% agonist activity) or presence of increasing (10⁻² M–10⁻⁵ M) concentrations of the spirolactones tested. Transactivation activities of MRs were determined from the luciferase activity normalized in terms of the β-galactosidase activity. Values are mean ± S.E.M. of three separate experiments.
Crystal structure of the MR_{S810L}\textsuperscript{-LBD} associated with SC9420 reported here reveals that the domain is composed of 11 α-helices (H1, H3–H12) and two short β-sheets, organized into three layers. The H12 helix is folded back toward the core of the domain, closing the ligand-binding pocket. The C-terminal extension is anchored to the region delineated by H8, H9, and H10 helices by numerous van der Waals contacts and by hydrogen bonds. This overall organization is similar to that of MR in its active state (Bledsoe et al., 2005; Fagart et al., 2005b; Li et al., 2005). Thus, the S810L mutation does not modify the positioning of the helices of the LBD. The H12 helix, which plays a crucial role in the activation process of the steroid receptors, adopts the same position in MR_{WT} and MR_{S810L}. This finding suggests that agonist binding to MR_{WT} and MR_{S810L} leads to the recruitment of transcriptional co-activators that occur in a similar way.

The crystal structure of MR_{S810L}\textsuperscript{-LBD} associated with SC9420 reveals that the Leu810 residue establishes short hydrophobic contacts with the C19 methyl of SC9420 and the Gln776 residue, which do not exist in MR_{WT}. It also reveals that SC9420 is anchored by the Gln776 and the Arg817 residues, and also by the Asn770 residue. This last contact was remarkable, because MR_{WT}-inactivation by spirolactones is based on the absence of contact between the Asn770 residue and spirolactones (Fagart et al., 1998). This led us to wonder about the contribution made by each of the contacts between spirolactones and the polar residues Asn770, Gln776, and Arg817 to the process of MRS810L activation. Mutagenesis analysis revealed that the ability of spirolactones to modulate the MR_{S810L}-activity is dramatically reduced by the N770A mutation. Thus, within MR_{S810L}, the contact between the Asn770 residue and spirolactones is not crucial for stabilizing MR_{S810L} in its active state, but does play a key role in the affinity of spirolactones. It is noteworthy that steroids harboring a C11 hydroxyl group, such as 11β-hydroxyprogesterone and cortisol, or a C11-C18 hemiketal group, as aldosterone, are not able to activate MR_{S810L}_{N770A} to a significant degree (Bledsoe et al., 2005).

Only progesterone and deoxycorticosterone, which have no C11 substitution, are able to activate MR_{S810L}_{N770A} (Bledsoe et al., 2005). Overall, these results show clearly that, in the context of MR_{S810L}, the anchoring of steroids having a C11 hydroxyl function or a C17 γ-lactone involves the Asn770 residue.

We wondered whether the two other polar residues Gln776 and Arg817, which anchor the C3 ketone function of spirolactones, play any role in stabilizing spirolactone-MR_{S810L} complexes in their active state. The replacement of the Gln776 or Arg817 residue by an alanine within MR_{S810L} abolishes their agonist character and restores the antagonist character that spirolactones display when bound to MR_{WT}. Furthermore, the potencies of spirolactones in inactivating MR_{WT}, MR_{S810L}_{Q776A}, and MR_{S810L}_{R817A} and activating MR_{S810L} follow the same order. This suggests that the contacts involving the Gln776 and Arg817 residues play a minor role in modulating the affinity of spirolactones for MR_{S810L} but are crucial for the activation of MR_{S810L} by spirolactones. Thus, the S810L mutation within MR reinforces the contacts between the C3 ketone function of spirolactones and the Gln776 and the Arg817 residues; each of these contacts becomes crucial for stabilizing the spirolactone-MR_{S810L} complexes in their active state. The activation of MR_{S810L} by progesterone also requires strong stabilizing contacts implicating the Gln776 and the Arg817 residues, whereas these contacts are dispensable for the activation of MR_{S810L} by C21-hydroxylated compounds, such as aldosterone and deoxycorticosterone (Fagart et al., 2005b). Thus, the Gln776 and the Arg817 residues are implicated in the mechanism of MR_{S810L} activation by steroids harboring a ketone function at the C3 position, but with no C21 hydroxyl function. These findings are consistent with the antagonist property of the synthetic ligand 5α-pregnane-20-one that is unable to contact the Gln776 and the Arg817 residues because of the absence of a C3 ketone function (Pinon et al., 2004).

We observed that the MR_{S810L}-activating potency of spirolactones depends on their C7 substituents. The structure reported here reveals that the side chain of the Met852 residue, a residue facing the C7 substituent of SC9420, adopts a folded-back conformation. In all the currently reported structures of MR-LBD associated with a ligand without the C7 substituent, the side chain of the Met852 residue adopts an extended conformation (Bledsoe et al., 2005; Fagart et al., 2005b; Li et al., 2005). This makes it likely that molecular adaptation of the side chain of the Met852 residue may be required to accommodate ligands with a C7 substituent. The folded-back conformation of the Met852 residue side chain creates a small groove surrounded by several hydrophobic residues. The C7 thioacetyl group of SC9420 fits well into this groove, where it makes numerous stabilizing van der Waals contacts. These contacts are responsible for the high MR_{S810L}-activating potency of SC9420. Docking experiments revealed that the C7 propyl group of RU26752 is accommodated in a similar way to the C7 thioacetyl group of SC9420, whereas the C7 carboxymethyl ester group of mexitrenone induces steric hindrance with the Phe829 residue. Thus, the accommodation of the C7 substituent within the ligand-binding cavity correlates well with the MR_{S810L}-activating potency of C7-substituted spirolactones.

In conclusion, mutagenesis analyses based on the crystal structure of MR_{S810L}\textsuperscript{-LBD} associated with SC9420, combined with docking experiments, make it possible to distinguish the residues responsible for the MR_{S810L} activation from those that modulate the ligands affinity. The contacts involving the Gln776 and the Arg817 residues are crucial for the activation of MR_{S810L} by spirolactones, whereas the Asn770 and the Met852 residues are key modulators of the affinity of spirolactones for MR_{S810L}. Another important conclusion of the study is that spirolactones also contact the Asn770 residue in MR_{WT}. This contact is not strong enough to stabilize the complex in its active state but is involved in the affinity of spirolactones for MR_{WT}. Because the MR_{S810L}-activating potencies of spirolactones correlate with their potencies in inactivating MR_{WT}, it can be surmised that the C7 substituents are accommodated in same way in MR_{WT} as in MR_{S810L}. Thus, the crystal structure of MR_{S810L} may provide a powerful tool for designing new, more effective, C7-substituted MR antagonists.

**Acknowledgments**

We thank M. Pirocchi and J.-L. Ferrer from the FIP-BM30A beamline at the European Synchrotron Radiation Facilities for assistance with data collection. We are also grateful to H. Richard-Foy and F. Gouilleux for providing plasmid pFC31Luc. We also thank colleagues for their critical reading of the manuscript.
References


Address correspondence to: Marie-Edith Rafestin-Oblin, INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon, 16, rue Henri Huchard, BP416, 75870 Paris, France. E-mail: oblin@bichat.inserm.fr